Ajanta Pharma announced its financial results for the second quarter and half-year ended September 30, 2026. The company reported a substantial 33% increase in revenue and a 49% surge in profit after tax (PAT) for the quarter, demonstrating robust financial performance. The half-year results also showed significant growth, with revenue up 29% and PAT up 40%.
Ajanta Pharma Reports Strong Financial Performance
Ajanta Pharma Limited has announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company showcased a remarkable performance, with consolidated revenue from operations increasing by 33% to ₹1,794 crore in the second quarter (Q2 FY2027) compared to ₹1,354 crore in Q2 FY2026. Profit after tax (PAT) also saw a significant jump of 49%, reaching ₹388 crore from ₹260 crore in the same period.
Half-Year Financial Highlights
For the first half of the fiscal year (H1 FY2027), Ajanta Pharma reported consolidated revenue of ₹3,420 crore, a 29% increase over H1 FY2026’s ₹2,656 crore. The company’s PAT for the half-year grew by 40% to ₹722 crore compared to ₹516 crore in the previous year. Adjusted EBITDA also showed strong growth, rising 47% to ₹543 crore in Q2 and 34% to ₹997 crore in H1.
Segment-Wise Performance
The company’s segment-wise performance indicates healthy growth across key markets. In Q2 FY2027, Branded Generics revenue reached ₹1,182 crore (up 23%), with India contributing ₹504 crore (up 16%). US Generics revenue stood at ₹484 crore (up 41%), and Africa Institution revenue was ₹116 crore (up 259%). The total consolidated revenue for Q2 FY2027 was ₹1,782 crore, marking a 33% increase year-on-year.
Investor Call and Further Details
Ajanta Pharma will host an Earnings Conference Call on October 30, 2026, at 16:00 hrs IST to discuss the financial performance and answer investor queries. Detailed financial results, including the statement of consolidated and standalone unaudited financial results, cash flow statements, and limited review reports, have been filed with the stock exchanges and are available on the company’s website.
Source: BSE
